Sweden · Delayed Price · Currency is SEK Corline Biomedical AB Company Description
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden.
The company’s products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting.
Its products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries.
The company also provides medical devices, such as coated stents and coated ablation catheter. Corline Biomedical AB was incorporated in 1991 and is based in Uppsala, Sweden.
| Country | Sweden |
| Founded | 1991 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Henrik Nittmar |
Contact Details
Address: Lefflersgatan 5 Uppsala, 754 50 Sweden | |
| Phone | 46 18 71 30 90 |
| Website | corline.se |
Stock Details
| Ticker Symbol | CLBIO |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0006887451 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Henrik Nittmar Ph.D. | Chief Executive Officer |
| Asa Holm | Chief Operating Officer |